Imavita is proud to announce the recent acquisition of a new Bioluminescence imaging (BLI 2D/3D) / Fluorescence imaging (FLI 2D) imaging apparatus to help in development of preclinical models.
Since December 2022, Imavita is working on this innovative imaging system (Newton 7.0 / Vilber) which will permit to generate non-invasive, bioluminescence imaging (BLI) and fluorescence imaging (FLI) quantitative data for pre-clinical models in place at Imavita in Applications of interest, and principally in the area of drug disposition (PK and PK/PD), oncology, osteo-articular disease and dermatology.
Bioluminescence imaging / BLI is available in 2D, but also in 3D (BLI tomography). Fluorescence imaging (FLI) is available in 2D.
This new apparatus will permit in vivo and ex vivo imaging for:
Monitoring the development of tumors and infections
Tracking cell migration
Targeting Biodistribution of drugs, molecules and nanoparticles
Visualization of vasculature and microcirculation
The benefits of this in vivo imaging modality are:
Easily and efficiently obtain calibrated quantitative data in preclinical models
Deepen understanding of disease mechanisms, disease progression and therapeutic responses
Manage costs and capture time course data by avoiding sacrifice of animal models
For more informations, do not hesitate to contact us.
Imavita is proud to announce new team members with the recent recruitment of Pierre-Yves Fortin and Pauline Auriol.
Pierre-Yves Fortin, PhD, Preclinical imaging, Project Leader, Pierre-Yves is a PhD graduated on 2011 and Post-Doc in 2020 with an important background and experience with preclinical models, preclinical imaging (fluorescence, bioluminescence, ultrasonography, elastography, etc…) in oncology.
Imavita is proud to announce a new team member with the recent recruitment of Claire Coustal.
Claire Coustal, Apprentice MSc, Research Scientist Assistant. Claire is actually graduating Master 2 (M2) Innovating Drug therapies and Biotherapeutics (“Biothérapies et Médicaments de Thérapie Innovante”) from University of Nantes, France. Claire works now at Imavita in the in vitro lab and in vivo models for drug efficacy evaluation principally in the field of Osteo-Articular disease and Neurology/Neuro-Inflammation.
IMAVITA S.A.S., an innovating technology company providing services in preclinical models of human pathologies associated with imaging and image analysis, announces its participation in the collaborative project PICSTEM.
This 2-years project will focus on the fields of osteo-articular diseases (Psoriatic Arthritis, Osteo-Arthritis and Ankylosing Spondyloarthritis) and neurology (neuro-inflammation in Recurrent-Remittent Multiple Sclerosis and Sciatic nerve inflammation).
IMAVITA will actively participate in this project by providing technical and scientific expertise and relevant preclinical models of human pathologies. This project will allow IMAVITA to develop new animal models and develop new translational services in preclinical and clinical imaging.
Imavita is proud to announce New Team members with the recent recruitment of Maud Chusseau and Julia Rochotte.
Maud Chusseau, MSc, Research Scientist, Maud is graduated from University of Lyon, France (Master Pharmacology / Animal experimentation 2007). Maud has several industry experiences (SeleXel, Endotis Pharma, Galapagos, Servier). Maud works now at Imavita in the in vitro lab and in vivo models for drug efficacy evaluation and has experience in qPCR, animals surgery and small animal imaging.
Julia Rochotte, PhD, Immunologist, Project Leader, Julia is a young PhD graduated on 2014. She has spent 7 years at the laboratory of the Center of Oncology Research of Toulouse (Centre de Recherche en Cancérologie de Toulouse (CRCT) U1037 INSERM / UPS / CNRS) with an important background in immunology and immuno-oncology.